Laboratorios Rubió leads the way in non-invasive diagnostics with the marketing of the groundbreaking non-invasive OWLiver® test to detect non-alcoholic fatty liver and associated conditions. Developed by biotechnology firm OWL Metabolomics, this innovative approach elevates Laboratorios Rubió’s standing in in-vitro diagnostics (IVD) and metabolomics within Spain and Latin America.
Pelayo Rubió, CEO of Laboratorios Rubió, celebrates the addition of this hospital-grade product to the company’s portfolio as “the consolidation of our company in the specific area of clinical research and diagnostic testing, and it represents progress in the healthcare process”.
According to the CEO of Laboratorios Rubió, Pelayo Rubió, leveraging non-invasive diagnostics like OWLiver®, it will help “identify high-risk patients with socially significant diseases such as dyslipidemias, in the case of Liposcale®, and non-alcoholic fatty liver diseases, in the case of OWLiver®”.
OWL Metabolomics CEO, Pablo Ortiz, echoed this sentiment, lauding the agreement as “a great opportunity for OWLiver® to become the test of choice for fatty liver screening in the near future”. He believes that “this strategic alliance will allow innovative technologies such as metabolomics to reach patients”.
It will facilitate the diagnosis of complex diseases such as steatohepatitis and achieving greater precision in determining cardiovascular risk”, concluded Ortiz.
The OWLiver® Test, founded on the study of metabolites, allows healthcare providers to gain insights into an organ’s metabolism. The non-invasive diagnostic, more economical than alternatives like ultrasound or MRI, is a breakthrough in patient-centric care within the National Health System in Spain.
Non-alcoholic fatty liver disease (NAFLD) affects between 20 and 30% of the Western population, related to obesity and diabetes. This asymptomatic condition necessitates early detection via non-invasive diagnostics to avoid serious and irreversible damage. Current projections suggest that NAFLD may soon become the leading cause of liver transplantation.
OWL Metabolomics is a biotech firm dedicated to identifying, validating, and globally commercializing non-invasive diagnostics for prevalent liver diseases. OWL Metabolomics has spearheaded diagnostic research into fatty liver with their groundbreaking products OWLiver® and OWLiver® Care, the world’s first lipidomics-based non-invasive in vitro tests for diagnosing NASH and NAFLD from a blood sample.